Andrew Adamovich

Brisbane biotech AdvanCell just raised a record $450 million

Brisbane radiopharmaceutical developer AdvanCell has closed an oversubscribed Series D round, led by Ally Bridge Group and Alpha Wave with several institutional investors returning, to fund late-stage prostate cancer trials and US manufacturing.

Cancer treatment biotech AdvanCell injects $178 million Series C

AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing

Sydney cancer-therapy developer AdvanCell has completed a US$112 million Series C that was oversubscribed, co-led by four investors, with Brandon Capital among new backers; three investor representatives join the board.

Also Startup Daily·SmartCompany·Forbes Australia